Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.
CpG
NFKBIZ
Toll-like receptor 9
cell line
chronic lymphocytic leukemia
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
02
10
2023
received:
26
06
2023
accepted:
24
10
2023
medline:
7
12
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) is a prototypic neoplasia in which malignant cells strongly depend on microenvironmental stimulations in the lymphoid tissues where they accumulate; leukemic cells are exposed to interaction with bystander and accessory cells, as well as inflammatory soluble mediators. Cell lines are frequently used to model the pathobiology of this disease; however, they do not always recapitulate leukemic cell growth and response to stimulation, and no data are available on Toll-like receptors (TLR) signaling in CLL cell lines. To address this gap, we analyzed HG3, MEC2, and PCL12 cell lines, before and after CpG stimulation, by RNA-sequencing followed by bioinformatic analyses and validation experiments. We identified NFKBIZ mRNA and the corresponding IkBz protein as robust markers of TLR9 activation in both MEC2 and PCL12, but not in HG3 cells. Next, we compared our current results with previous results obtained with primary CLL patient samples and were able to conclude that MEC2 is most similar to the patients' cells in terms of global responsiveness to TLR stimulation; in particular, MEC2 better resembles the samples of patients, as it is characterized by high expression levels of IkBz, but with a lower number of genes regulated.
Identifiants
pubmed: 37881888
doi: 10.1002/2211-5463.13726
pmc: PMC10699106
doi:
Substances chimiques
Toll-Like Receptor 9
0
Toll-Like Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2367-2374Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 23088
Organisme : Ministero della Salute
ID : RF-2018-12367072
Informations de copyright
© 2023 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Cancer Res. 2019 Jan 15;79(2):360-371
pubmed: 30498085
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Blood. 2010 Feb 25;115(8):1605-9
pubmed: 20018917
Haematologica. 2011 Mar;96(3):353-5
pubmed: 21357715
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Immunity. 2015 Sep 15;43(3):475-87
pubmed: 26320658
PLoS One. 2015 Jun 25;10(6):e0130195
pubmed: 26110819
Leuk Res. 1999 Feb;23(2):127-36
pubmed: 10071128
Clin Cancer Res. 2013 Jan 15;19(2):367-79
pubmed: 23224401
Nature. 2004 Jul 8;430(6996):218-22
pubmed: 15241416
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Leukemia. 2022 Aug;36(8):1961-1968
pubmed: 35614318
Blood. 2008 Jul 1;112(1):188-95
pubmed: 18292287
J Immunol. 2015 Aug 1;195(3):901-23
pubmed: 26136429
Blood. 2022 Dec 1;140(22):2335-2347
pubmed: 36084319
Hematol Oncol Clin North Am. 2021 Aug;35(4):687-702
pubmed: 34174980
Oncoimmunology. 2012 Jan 1;1(1):18-27
pubmed: 22720208
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Eur J Immunol. 2023 Oct;53(10):e2350418
pubmed: 37561992
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Leukemia. 2012 Jul;26(7):1584-93
pubmed: 22343732
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Blood. 2021 Jun 3;137(22):3064-3078
pubmed: 33512408
Br J Haematol. 2020 May;189(3):475-488
pubmed: 32057093
Haematologica. 2017 Nov;102(11):1901-1912
pubmed: 28775123
Leuk Lymphoma. 2013 Aug;54(8):1769-79
pubmed: 23297799
Blood. 2000 Feb 1;95(3):999-1006
pubmed: 10648415